Currently there are only two predictive biomarkers for immunotherapy in NSCLC by the US FDA, i.e., tumor PD-L1 expression assessed by immunohistochemistry (IHC) [4] and tumor mutation burden (TMB) [5,6,7]. This evidence concerns the gene CD274 and neoplasm.